TwoToBiotech
Novel Human Peptide Hormones to Treat Diabetes
Company Overview
Snapshot
Founded in January 2008 by Orly Devary and Tamara Sandler, TwoToBiotech operates with 1–10 employees. The company has raised $500,000 across one funding round from one investor. In July 2020, TwoToBiotech secured Pre-Seed funding.
Business overview
TwoToBiotech is a Health Tech & Life Sciences company focused on developing novel human peptide hormones to treat diabetes and autoimmune diseases. The company's core technology involves identifying and developing specific monoclonal antibodies against peptide hormones, such as P3, which is expressed in activated immune cells. TwoToBiotech is also developing APC1 for type 2 diabetes treatment and has isolated a novel human cardiac peptide with potential for glucose metabolism regulation. The company operates in the Pharmaceuticals sector, targeting the United States market with a B2B business model.
Log in to access full profile ›Company Intelligence Q&A
- What is TwoToBiotech's primary focus?
- TwoToBiotech focuses on developing novel human peptide hormones to treat diabetes and autoimmune diseases, leveraging its research into peptides like P3 and APC1.
- When was TwoToBiotech founded and by whom?
- TwoToBiotech was founded in January 2008 by Orly Devary and Tamara Sandler.
- What is the status of TwoToBiotech?
- TwoToBiotech is currently Non Active and ceased to operate in March 2022.
- What was TwoToBiotech's last known funding event?
- In July 2020, TwoToBiotech secured Pre-Seed funding, raising $500,000 from one investor.
- What markets does TwoToBiotech target?
- TwoToBiotech targets the United States market with its pharmaceutical developments.